VIDEO: High-volume hemodiafiltration therapy can benefit US patients
Click Here to Manage Email Alerts
Key takeaways:
- High-volume hemodiafiltration may assist in the removal of middle-sized and larger molecules.
- Benefits include the use of less saline and more efficient priming and rinsing.
SAN DIEGO — In this video exclusive from ASN Kidney Week, nephrologists underscore the beneficial potential of using of high-volume hemodiafiltration therapy in the United States.
Nephrologists Robert J. Kossmann, MD, FACP, FASN, executive vice president and chief medical officer, Care Enablement, at Fresenius Medical Care, and Michael Anger, MD, FACP, FASN, senior vice president, medical officer, In-Center Dialysis and Quality & Regulatory, at Fresenius Medical Care, described treatment advantages of hemodiafiltration compared with hemodialysis. Hemodiafiltration combines convective and diffusive dialysis to enhance molecule removal.
“[High-volume] hemodiafiltration is a therapy that has been available elsewhere outside of the [United States] for decades, and it is different than the type of dialysis than is currently provided because it adds convective therapy to the diffusion that we provide now,” Anger told Healio. “And convective therapy is the infusion of additional fluid that then gets removed and helps assist in the removal of middle and larger molecules by solving drag.”
Benefits, such as less saline use and more efficient priming and rinsing, were highlighted in findings from the CONVINCE trial published in the New England Journal of Medicine, which reported a 23% reduction in mortality rates among patients on high-volume hemodiafiltration. The data also showed improvements in patient-reported outcomes.
“We anticipate this is going to be quite a practical device for novel therapy for the [United States],” Kossmann told Healio. “The beauty of the complexity of the device is the simplicity of use. The device is complex, but actually utilizing the device is not because of the built-in algorithms and some of the workflow enhancements.”
Fresenius received FDA 510(k) clearance for its proprietary 5008X hemodialysis system in February 2024.
Reference:
Blankestijn PJ, et al. N Engl J Med. 2023;doi.org/10.1056/NEJMoa2304820.
Collapse
Healio Interviews.
Read more about
Click Here to Manage Email Alerts